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CASE STUDY
Migraine treatment: a chain of adverse 
effects
Tiago Sousa Veloso1,2* and Mariana Seixas Cambão3
Abstract 
This clinical vignette presents a 14 years old female, with a past medical history relevant only for migraine with typical 
aura of less than monthly frequency, complaining of a severe unilateral headache with rising intensity for the previ-
ous 4 h, associated with nausea, vomiting, photophobia and phonophobia. This episode of migraine with aura in a 
patient with recurrent migraine was complicated by side effects of medical diagnostic and therapeutic procedures 
(extrapyramidal symptoms, delirium, post-lumbar puncture headache, hospital admission) all of which could have 
been prevented—quaternary prevention. This case illustrates several important messages in migraine management: 
(1) use of acetaminophen is not based in high-quality evidence and better options exist; (2) among youngsters, dom-
peridone should be preferred over metoclopramide because it does not cross the blood–brain barrier; (3) moderate 
to severe migraine crisis can be managed with triptans in teenagers over 12 years old; (4) it is important to recognize 
adverse drug effects; (5) harmful consequences of medical interventions do occur; (6) the school community must be 
informed about chronic diseases of the young.
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Background
Primum non nocere is a cornerstone principle of ars med-
ica (medical practice). Harmful consequences can derive 
from everyday drug treatments and it is only through a 
high-degree of suspicion that certain etiological diagno-
sis can be made. Prescribing cascades and careless use 
of ancillary studies can only be avoided if adverse drug 
effects are foreseen and identified—quaternary preven-
tion. This case illustrates several important messages in 
quaternary prevention during migraine management.
Headaches are a common complaint among adoles-
cents (from 8 to 23 %) (Lewis et al. 2004) and it is esti-
mated that two-thirds of sufferers are managed in 
primary care (American Headache Society and Primary 
Care Migraine Partnership 2004). Among the main types 
of primary headache, migraine is the leading cause of 
disability, and alone is itself the eighth major cause of 
disability among both men and women worldwide (Vos 
et al. 2010).
The clinical vignette here presented pictures the harm-
ful effects that may derive from medical interventions 
and how they may change the natural history of migraine. 
It is important not only to recognize disease but also to 
anticipate and consider potential adverse effects of medi-
cal practice in order to avoid harming patients (primum 
non nocere).
Case presentation
A 14-year-old girl presented to her primary care center 
with a severe unilateral headache that had progressed over 
a 4 h period from typical aura to moderate pain with pho-
tophobia and phonophobia to vomiting and to high-inten-
sity headache. Her relevant past medical history included 
Migraine with Typical Aura (<1 per month) diagnosed at 
12  years old after excluding major organic disease. The 
physical examination was notable for the normal blood 
pressure and temperature, absence of neurologic deficits 
and meningeal signs, as well as the absence of any other 
sign or symptom suggestive of a secondary headache. At 
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this time, the whole clinical picture was compatible with 
an increased intensity flare of the previously diagnosed 
migraine with typical aura due to her lack of opportunity 
to administer herself the abortive therapy at the appropri-
ate moment in time (earlier that morning, during a school 
class, she had felt the beginning of the aura; unfortunately, 
her teacher did not allow her to leave the room in order to 
have access to the abortive treatment).
At the primary care center, she received intravenous 
acetaminophen (paracetamol) and metoclopramide. No 
more than half an hour had passed when she started 
developing dystonia of the upper limbs. No improve-
ment of her presenting headache was noted. Decision 
was made of transferring her to the Pediatrics emergency 
unit for a diagnostic and therapeutic procedure. After 
admission to the hospital, these extrapyramidal symp-
toms were managed with biperiden (a centrally acting 
antiparkinsonian anticholinergic drug). A few minutes 
later the teenager became confused, spatially disoriented 
and with short-term memory disturbance. This acute 
confusional state lead to a diagnostic procedure which 
included a lumbar puncture and the consideration of an 
electroencephalogram, although not immediately avail-
able. After disclosure of the laboratory results, which 
were entirely unremarkable, the patient remained under 
medical supervision for several hours and the delirium 
gradually faded away. This evolution helped reinforcing 
the etiological role of biperiden. During this time, a spon-
taneous improvement from the migraine was noted as 
well as total recovery of orientation and confusion. Later 
on, after admission to the Pediatrics ward, the patient 
complained of another headache, but this time with a 
different presentation (frontal pain, associated with the 
upright position, relieved by lying down). A post-lumbar 
puncture headache was diagnosed, which prolonged her 
hospital stay for over 48 h and her home rest and school 
absence for the following 5  days. At the time of hospi-
tal discharge a neurology consultation was scheduled in 
order to decide for the need of further diagnostic study 
for the migraine. At that neurology appointment, a brain 
magnetic resonance imaging (MRI) scan was requested 
(recall that 2 years before, at her 12-years-old, a diagnos-
tic procedure for a recurrent headache, including a brain 
computerized tomography (CT) scan, had been done 
and supported the migraine diagnosis). Indeed, the brain 
MRI turned out to be, not surprisingly, unremarkable.
Discussion
This case illustrates several important messages in 
migraine management.
1. The use of acetaminophen as migraine abortive 
(symptomatic) therapy has limited evidence of 
efficacy and is not a first-line treatment in major 
national (Pereira-Monteiro 2009; Portuguese Head-
ache Society 2010) nor international (Steiner et  al. 
2007, 2011) guidelines. Acetaminophen use did not 
even reduce the need for rescue medication when 
compared to placebo (Damen et al. 2005). Alternative 
drugs exist supported by high-quality evidence (at 
least one randomized-controlled trial and low alpha 
and beta types of error)—for instance: ibuprofen or 
acetylsalicylic acid (the latter is not intended for use 
in people under 12 or under 16 if feverish, although 
the relationship between aspirin intake and Reye syn-
drome is not supported by sufficient facts) (Schor 
2007). Moreover, intravenous acetaminophen has 
not been evaluated in randomized controlled trials 
in the pediatric population, and has shown not to be 
superior to placebo in treating severe acute migraine 
attacks in adults (Leinisch et al. 2005).
2. Among youngsters, domperidone should be pre-
ferred over metoclopramide (Pereira-Monteiro 2009) 
because it does not cross the blood–brain barrier 
(Teixeira 2001). Metoclopramide was even associ-
ated with a 31% increased odds of emergency depart-
ment revisit than other antiemetic drugs (Bachur 
et  al. 2015). Domperidone is the only antiemetic 
drug licensed for use in children up to 12 years of age 
(Evers et al. 2009).
3. Moderate to severe migraine crisis in teenagers over 
12 years old can be managed with sumatriptan (Win-
ner et al. 2000; Curran et al. 2005; Cady and Schreiber 
2006; Evers et al. 2009, Pereira-Monteiro 2009; Gold-
man and Meckler 2015), rizatriptan (Ahonen et  al. 
2006) or zolmitriptan (Evers et al. 2006; Lewis et al. 
2007) and the efficacy of these drugs has been sup-
ported by moderate to high quality evidence. The 
off-label use of triptans is still a matter of debate, 
however more recently sumatriptan nasal spray and 
zolmitriptan nasal spray have been approved for ado-
lescents in Europe; almotriptan has been approved 
for adolescents in the USA, as has rizatriptan for 
patients aged 6–17 years (Wöber-Bingöl 2013).
4. Not only is it important to be familiar with the most 
common adverse effects of drugs prescribed (Garjón 
2011), but it is a matter of utmost importance being 
able to recognize them. Mastering dosing, adverse 
effects and interactions will place physicians in a bet-
ter position to prevent errors and anticipate prob-
lems (Schiff et al. 2011). Whenever possible, educate 
patients about possible adverse effects to ensure that 
they are recognized as early as possible (Schiff et al. 
2011).
5. Harmful consequences of medical interventions do 
occur, deteriorate patients’ quality of life, make diag-
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nosis and management of patients’ disease more dif-
ficult, and can lead to what is known as “prescription 
cascade”, that is, treatment of the undesirable effect of 
a drug by another drug (Garjón 2011). A major pre-
scribing cascade scenario has been illustrated in this 
clinical report: biperiden, as a muscarinic receptor 
antagonist, was used to control the extrapyramidal 
motor symptoms (Brocks 1999) induced by meto-
clopramide. Biperiden can be administered through 
oral, intravenous and intramuscular routes in dos-
ages starting from 1 to 2  mg per day up to 12  mg/
day (in 2 or 3 separate doses) or even higher (doses 
of 40  mg/day have been reported in severe dysto-
nia patients) (Oztekin et al. 1991). Toxicity is mainly 
dependent on its anticholinergic properties, and 
instead of others of its class, no reports of fatalities 
due to biperiden seem to be available (Gjerden and 
Slørdal 1998). Reviewing current drug therapy is an 
essential component of medical care. Therefore, care-
ful consideration should be given to any new symp-
tom in order to decide whether the development of 
a new medical condition could be the presentation 
of an atypical adverse drug effect to an existing drug 
therapy (Rochon 2014). Moreover, if we enlarge the 
concept of prescribing cascade and allow it to include 
a diagnostic domain, then one diagnostic prescribing 
cascade is also illustrated by this clinical vignette: the 
acute confusional state induced by biperiden, result-
ing from its anticholinergic properties (Standaert and 
Young 2001), was conducive to a broader ancillary 
work-up, including a lumbar puncture (which in this 
case became complicated by a post-lumbar puncture 
headache) and a brain MRI.
6. Last but not least, it is necessary to inform and 
involve the school community in the care of children 
and teenagers with chronic diseases as this may posi-
tively contribute to better health outcomes (Yonker 
2009). This case report illustrates how a seemingly 
unimportant authorization for leaving the class (in 
order to have access to a glass of water and some 
drug treatment) could have avoided the escalat-
ing severity of headache and the undesirable related 
morbidity.
The optimal treatment of migraine must be custom-
ized to the patient and to the attack. Patient empower-
ment must be promoted to enhance personal control of 
migraine, to reduce use of resources, to rapidly restore 
ability to function, to improve patient satisfaction and to 
minimize use of back-up and rescue medications (Lewis 
et  al. 2004). Should a migraine episode develop to a 
full-blown crisis, a stratified care approach is advisable 
(as opposed to a stepped care approach) (Lipton 1998; 
Rothrock 2012) which will guide management accord-
ing to peak intensity, time to peak intensity, any asso-
ciated symptoms and disability. The pharmacological 
treatment of the status migrainosus may include aceta-
minophen, a non-steroidal anti-inflammatory drug (e.g. 
ibuprofen or naproxen), a triptan (consider the nasal 
route when emetic symptoms are present), dihydroer-
gotamine, selected opioids and selected corticosteroids. 
For many children, merely inducing sleep is effective. 
Anti-emetics should also be considered as necessary.
Conclusions
This case illustrates several important messages in qua-
ternary prevention during migraine management: (1) use 
of acetaminophen is not based in high-quality evidence 
and better options exist; (2) among youngsters, domperi-
done should be preferred over metoclopramide because 
it does not cross the blood–brain barrier; (3) moderate 
to severe migraine crisis can be managed with triptans 
in teenagers over 12 years old; (4) it is important to rec-
ognize adverse drug effects; (5) harmful consequences 
of medical interventions do occur; (6) the school com-
munity must be informed about chronic diseases of the 
young.
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